discovery studio 3d-qsar-based pharmacophore modeling process (Accelrys)
90
Structured Review
Accelrys
discovery studio 3d-qsar-based pharmacophore modeling process
Discovery Studio 3d Qsar Based Pharmacophore Modeling Process, supplied by Accelrys, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/discovery+studio+3d-qsar-based+pharmacophore+modeling+process/3d+qsar+pharmacophore+generation+module/pm36708643-44-4-0
Average 90 stars, based on 1 article reviews
Discovery Studio 3d Qsar Based Pharmacophore Modeling Process, supplied by Accelrys, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/discovery+studio+3d-qsar-based+pharmacophore+modeling+process/3d+qsar+pharmacophore+generation+module/pm36708643-44-4-0
Average 90 stars, based on 1 article reviews
discovery studio 3d-qsar-based pharmacophore modeling process - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Roxadustat and its failure: A comparative dynamic study. Article Snippet: Roxadustat, a small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase domain 2 (HIF-PHD2) has been recently overruled by the American Food and Drug Administration (FDA) in Phase 3 clinical trials.. This study provides insights into the dynamics of Roxadustat with PHD2 and proposes two FDA-approved drugs; Pemetrexed and Valrubicin to treat chronic kidney disease (CKD).. Role of chemical scaffolds such as synthetic pyrimidine-based antifolate is found critical for PHD2 inhibitory activity, which is concurrent with the experimental findings for stimulating Endogenous erythropoietin (EPO) gene expression. |